These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21498726)

  • 1. 15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment.
    Krause FS; Walter B; Ott OJ; Häberle L; Weiss C; Rödel C; Wullich B; Sauer R
    Anticancer Res; 2011 Mar; 31(3):985-90. PubMed ID: 21498726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment proliferation and local control in bladder cancer after radiotherapy with or without concurrent chemotherapy.
    Weiss C; Rödel F; Ott O; Engehausen DG; Papadopoulos T; Sauer R; Rödel C
    Strahlenther Onkol; 2007 Oct; 183(10):552-6. PubMed ID: 17896086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of holmium laser resection for primary nonmuscle-invasive bladder cancer versus transurethral electroresection: single-center experience.
    Zhu Y; Jiang X; Zhang J; Chen W; Shi B; Xu Z
    Urology; 2008 Sep; 72(3):608-12. PubMed ID: 18649930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer.
    Streeper NM; Simons CM; Konety BR; Muirhead DM; Williams RD; O'Donnell MA; Joudi FN
    BJU Int; 2009 Feb; 103(4):475-9. PubMed ID: 18990174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Organ-sparing treatment of advanced bladder cancer: paclitaxel as a radiosensitizer.
    Müller AC; Diestelhorst A; Kuhnt T; Kühn R; Fornara P; Scholz HJ; Dunst J; Zietman AL
    Strahlenther Onkol; 2007 Apr; 183(4):177-83. PubMed ID: 17406798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral lymphatics and lymphatic vessel invasion detected by D2-40 are essential for lymph node metastasis in bladder transitional cell carcinoma.
    Ma Y; Hou Y; Liu B; Li X; Yang S; Ma J
    Anat Rec (Hoboken); 2010 Nov; 293(11):1847-54. PubMed ID: 20730866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transurethral resection for muscle-invasive bladder cancer.
    Kondás J; Váczi L; Szecsó L; Kondér G
    Int Urol Nephrol; 1993; 25(6):557-63. PubMed ID: 8175277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy.
    Weiss C; von Römer F; Capalbo G; Ott OJ; Wittlinger M; Krause SF; Sauer R; Rödel C; Rödel F
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1455-60. PubMed ID: 19231102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updated results of bladder-sparing trimodality approach for invasive bladder cancer.
    Zapatero A; Martin de Vidales C; Arellano R; Bocardo G; Pérez M; Ríos P
    Urol Oncol; 2010; 28(4):368-74. PubMed ID: 19362865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years.
    Serretta V; Pavone C; Ingargiola GB; Daricello G; Allegro R; Pavone-Macaluso M
    Eur Urol; 2004 Jun; 45(6):730-5; discussion 735-6. PubMed ID: 15149744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of surveillance in the treatment of patients with muscle-invasive bladder cancer after chemotherapy.
    Hellenthal NJ; Ramirez ML; Evans CP; Devere White RW
    BJU Int; 2010 Feb; 105(4):485-8. PubMed ID: 19849694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?
    Weiss C; Wolze C; Engehausen DG; Ott OJ; Krause FS; Schrott KM; Dunst J; Sauer R; Rödel C
    J Clin Oncol; 2006 May; 24(15):2318-24. PubMed ID: 16710030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. External beam radiation therapy followed by interstitial radiotherapy with iridium-192 for solitary bladder tumours: results of 111 treated patients.
    van Onna IE; Oddens JR; Kok ET; van Moorselaar RJ; Bosch JL; Battermann JJ
    Eur Urol; 2009 Jul; 56(1):113-21. PubMed ID: 18722048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elective bladder preservation with multimodality treatment for bladder cancer.
    Mayadagli A; Kocak M; Demir O; Karabulut Gul S; Ozkan A; Parlak C; Yaprak G; Gumus M
    J BUON; 2012; 17(3):483-9. PubMed ID: 23033286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiochemotherapy after transurethral resection is an effective treatment method in T1G3 bladder cancer.
    Akçetin Z; Todorov J; Tüzel E; Engehausen DG; Krause FS; Sauer R; Schrott KM; Rödel C
    Anticancer Res; 2005; 25(3A):1623-8. PubMed ID: 16033071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of immediate second resection of the tumor bed to improve the effectiveness of transurethral resection of bladder tumor.
    Kim W; Song C; Park S; Kim J; Park J; Kim SC; Cho YM; Hong B; Ahn H
    J Endourol; 2012 Aug; 26(8):1059-64. PubMed ID: 22390720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience.
    Iida S; Kondo T; Kobayashi H; Hashimoto Y; Goya N; Tanabe K
    Int J Urol; 2009 Mar; 16(3):287-92. PubMed ID: 19207115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined-modality treatment and organ preservation in bladder cancer. Do molecular markers predict outcome?
    Weiss C; Rödel F; Wolf I; Papadopoulos T; Engehausen DG; Schrott KM; Sauer R; Rödel C
    Strahlenther Onkol; 2005 Apr; 181(4):213-22. PubMed ID: 15827690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy.
    Weiss C; Wittlinger M; Engehausen DG; Krause FS; Ott OJ; Dunst J; Sauer R; Rödel C
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1502-6. PubMed ID: 17935905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.